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The staging and therapy of breast cancer patients is currently
undergoing an evolution toward breast conservation, limited 
axillary node dissection (sentinel node biopsy) and more frequent
use of both neoadjuvant and adjuvant chemotherapy. In order to
support this evolution, better prognostic and predictive markers are
needed which can be applied to the primary breast carcinoma. In
the present study we investigated apoptosis, p27 and p53 retrospec-
tively in 181 human breast cancer specimens and the relevance of
these markers to the biological behaviour of breast cancer.
Cell cycle arrest has been associated with checkpoints regulated
by cyclin-dependent kinase (cdk) complexes and their inhibitors
(cki’s). The cyclin-dependent kinase inhibitor p21Cip1 is a critical
downstream effector in the p53-specific pathway of growth
control in mammalian cells (El-Deiry et al, 1993; Harper et al,
1993; Noda et al, 1994). In a previous study, we have shown that,
in human breast cancer, p21 expression is strongly related to
cellular differentiation and patient survival (Jiang et al, 1997).
Other investigators have observed similar results in lung and colon
cancers (El-Deiry et al, 1995; Doglioni et al, 1996; Marchetti et al,
1996). p27Kip1, another cyclin-dependent kinase inhibitor, which
was more recently cloned (Polyk et al, 1994a,b; Toyoshima et al,
1994) has been shown to inhibit the kinase activity of cyclin A-
cdk2, cyclin B-cdk2, cyclin D-cdk4 and cyclin E-cdk2, by
preventing cdk activation, and thereby precluding cells from
entering S-phase (Polyk et al, 1994a,b; Toyoshima et al, 1994).
p27 protein levels and/or activity are up-regulated by growth
inhibitory cytokines including transforming growth factor-b
(TGF-b) (Reynisdottir et al, 1995). p27 protein levels also have
been associated with density arrest and growth factor deprivation
(Gray-Bablin et al, 1997). Loss of p27, a negative cell-cycle regu-
lator, therefore may contribute to oncogenesis and tumour progres-
sion (Alessandrini et al, 1997).
Programmed cell death (or apoptosis) represents another critical
cellular response to a variety of external stimuli including 
genotoxic (DNA-damaging) stimuli. The p53 protein is a pivotal
component of pathways leading to growth arrest as well as apop-
tosis, suggesting that the two processes may act in concert (Levine
et al, 1997). Many studies have established that DNA damage
leads to up-regulation and activation of p53, which can result
either in arrest at the G1-S checkpoint, by transcriptional activation
of p21Cip, or induction of apoptosis. It also has been shown that
overexpression of p27 in human breast cancer cells can promote
apoptosis (Katayose et al, 1997). Because of the relationships
between p27, p53 and apoptosis and their potential regulation of
the biology of breast carcinoma cells, we decided to examine the
prognostic significance of these markers in human breast cancer.
MATERIALS AND METHODS
Samples
Breast cancer specimens were obtained from 181 patients.
Histological types were determined according to the WHO
criteria. Samples were obtained between 1986 and 1990 from
patients at the Department of Surgery, Cancer Hospital of
Shanghai Medical University following an approved institutional
review board protocol.
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Immunohistochemical analysis
Immunohistochemical analysis of p27 and p53 protein expression
in breast carcinoma samples was performed. Paraffin sections 
(5 mm) obtained from biopsies were subjected to immunoperoxi-
dase staining with murine monoclonal antibodies: anti-human p27
(PharMingen, San Diego, CA), and anti-human p53 (Oncogene
Research, Cambridge, MA 02142). Tissue sections were deparaf-
finized with two changes of xylene for 5 min, followed by two
washes of absolute ethanol, 95% and 70% ethanol for 3 min each
and then treated with 2% H2O2 in methanol for 30 min to quench
endogenous peroxidase. The sections were blocked with diluted
goat serum for 30 min. The sections were incubated with 50 ml
monoclonal mouse anti-human p27 (dilution of 1:50) or p53 
antibody (dilution of 1:50) at room temperature for 1 h. Control
sections were incubated in the absence of primary antibody. The
sections were washed and then incubated with diluted (1:200)
biotinylated goat anti-mouse IgG for 1 h at room temperature,
followed by a 60-min incubation with ABC reagent. Staining was
developed using 3,3¢-diaminobenzidine for varying times to opti-
mize target/background staining. Cells were considered positive
for p27 and p53 when distinct nuclear staining was identified.
Representative areas of the tumour, i.e. areas in which staining was
most interpretable, were randomly chosen for study. The
percentage of cells demonstrating positive nuclear staining 
was evaluated by counting 1000 cells in random high power fields.
Two observers counted both markers. Interobserver variation was
addressed by averaging the individual values. Interobserver varia-
tion usually did not differ by more than 10%.
Apoptosis assay
Apoptosis was detected by labelling the 3’ OH ends of DNA
utilizing digoxigenin-nucleotide incorporation by terminal
deoxynucleotidyl transferase, a type of TUNEL method.
Antidigoxigenin antibodies and immunoperoxidase staining were
utilized with the ApopTag detection system (Oncor, Gaithersburg,
MD, USA). All sections were coded and scored blindly by two
Table 1 Characteristics of breast cancer patients in study
Characteristic Number (n = 181) (%)
Menopause
Premenopausal 46.4
Postmenopausal 53.6
Tumour size
≤ 2 cm 30.9
> 2 cm 69.1
TNM Stage
1 18.2
2 55.2
3 26.6
LN status
LN(–) 46.4
LN(+) 53.6
Grade
1 47.5
2 33.1
3 19.4
ER status
ER(+) 43.6
ER(–) 56.4
p27
Low 69.1
High 30.9
p53
Low 65.0
High 35.0
AI
Low 61.3
High 38.7
Disease status
Relapses 28.7
No relapses 71.3
Survival status
Dead 11
Alive 89
Therapy
Surgery + chemotherapy 71.3
Surgery only 28.7
Figure 1 p27 and AI in two infiltrating ductal carcinomas. (A) Apoptotic cells
(brown nuclear staining) comprised 5% of all cells in this case whose AI
would fall in the AI (H) category, magnification ´ 250. (B) p27 immunopositive
(brown nuclear staining) cells comprise approximately 60% of all cells in this
case whose p27 would fall in the p27 (H) category, magnification ´ 100
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observers in an identical manner as was done for p27 and p53. The
percentage of cells showing positive nuclear staining was deter-
mined as the apoptotic index (AI).
Steroid receptor assays
The standard dextran coated-charcoal assay was used as described
previously (Kute et al, 1992). In all cases, the Scatchard plot
analysis was done with eight points, and the protein content in the
reaction was 1 mg ml–1. Receptor levels of 10 fmol mg–1 of protein
or greater were considered positive. The biochemical measure-
ments were subsequently confirmed by ER immunohistochemistry.
We used the biochemical determinations of ER in the final analysis
because they were more quantitative.
Statistical analysis
Comparisons of the differences among the expression of p27, p53
and AI were made using the two tailed Student’s t-test. Spearman’s
rank-based correlation was used to assess the relationship between
the variables. The Kaplan–Meier method was utilized to estimate
relapse-free and overall survival times. Log-rank test was used to
assess the univariate effect of the expression of p27, 53, AI and
other variables on the relapse-free and overall survival times.
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Figure 2 (A) The relationship between p27, p53 and AI in breast cancer samples and axillary lymph node metastasis. (B) The relationship between p27, p53
and AI with ER status in breast cancer samples. (C) The relationship between p27, p53 and AIp27 and apoptosis in breast carcinoma 1575
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Cox’s proportional hazards model was used to examine the differ-
ences in overall survival and relapse-free survival after adjustment
for other covariates.
RESULTS
The 181 breast cancer patients whose specimens were collected in
1986–1990 were followed-up for periods up to 12 years; the
median follow-up time was 5 years. Table 1 gives the characteris-
tics of the patients and their tumours. We used the log-rank test to
assign divisions providing the best prognostic separations of our
patient database. We defined low AI (L) as those tumours with an
AI ≤ 2.10% and high AI (H) > 2.10% (Figure 1A). We found that
38.7% of the tumours showed AI (H) and 61.3% had AI (L). We
defined low p27 as tumours in which ≤ 50% of the cells showed
nuclear staining and high p27 as tumours in which > 50% of the
cells showed nuclear staining (Figure 1B). We found that 30.9% of
the tumours showed p27 (H) and 69.1% showed p27 (L). In this
study we chose to assign no significance to p27 cytoplasmic
staining which was present occasionally. With respect to p53 we
defined tumours with ≤ 15% of the cells immunoreactive as low
p53 and tumours with > 15% of the cells immunoreactive as high
p53. With this division 65.0% of the tumours were p53 (L) and
35.0% were p53 (H). In this study we deviated from the traditional
cutoff of 10% for p53 because by log-rank test analysis, 15%
provided the best prognostic separation of our patient population.
Our results demonstrated that low p27, low AI and high p53
significantly correlated with lymph node metastasis (Figure 2A).
When the relationship between p27, AI and p53 and ER expres-
sion was examined, p53 inversely correlated, AI directly corre-
lated, and p27 did not correlate with ER positivity (Figure 2B).
Furthermore, we found an inverse relationship between p27 and
p53. AI also inversely correlated with p53 expression, but directly
correlated with p27 expression (Figure 2C). A significant associa-
tion was also seen between low p27, low AI, high p53 and high
histological grade (Table 2).
On the basis of stratifying our patients into p27/p53 (L vs H) and
p27/AI (L vs H) phenotypes, we examined their overall survival
and relapse rates. p27 (L)/AI (L) and p27 (L)/p53 (H) exhibited
high relapse and death rates (48–55%) (P < 0.05) (Table 3).
Table 2 Correlation between histological grade of breast cancer and p27,
p53 and AI
Histological grade
Rsa P
p27 –0.303 0.002
p53 +0.454 0.004
AI –0.479 0.0001
aSpearman test: Rs: Correlation coefficient.
Table 5 Multivariate analysis with Cox’s proportional hazards model for
prognostic factors for breast cancer patients
Factors
Relapse-free survival Overall survival
analysis Risk ratio (CI) P-value Risk ratio (CI) P-value
Age 1.0875 (0.987–1.169) 0.1826 1.2553 (1.163–1.361) 0.3393
LN status 2.2939 (2.218–2.376) 0.0018 2.3701 (2.202–2.398) 0.0197
Tumour size 1.2345 (1.171–1.391) 0.3577 1.0761 (0.982–1.165) 0.7961
ER status 0.8314 (0.769–0.893) 0.6341 0.6352 (0.539–0.735) 0.2766
p27 0.4132 (0.323–0.514) 0.042 0.3691 (0.252–0.451) 0.0495
p53 0.3317 (0.258–0.417) 0.0332 0.3439 (0.241–0.436) 0.0465
AI 0.7235 (0.639–0.807) 0.3411 0.8773 (0.787–0.962) 0.9385
Table 6 Multivariate analysis of relapse-free and overall survival in lymph
node-negative patients
Factors Relapse-free survival Overall survival
Risk ratio (CI) P-value Risk ratio (CI) P-value
p27 0.1734 (0.054–0.0586)0.003 0.2646 (0.070–0.996) 0.049
p53 0.2891 (0.056–0.098) 0.023 0.2561 (0.078–0.981) 0.032
Grade 3.5461 (1.124–11.19) 0.031 2.555 (0.524–12.46) 0.246
TNM stage 5.1691 (0.582–31.37) 0.074 3.9162 (0.591–25.93) 0.157
ER status 0.8723 (0.719–0.987) 0.817 0.7343 (0.572–0.896) 0.633
AI 1.3561 (1.231–2.345) 0.341 0.8911 (0.761–1.234) 0.691
Table 7 Multivariate analysis of relapse-free and overall survival in lymph
node-positive patients
Factors Relapse-free survival Overall survival
Risk ratio (CI) P-value Risk ratio (CI) P-value
p27 0.4567 (0.233–0.895) 0.022 0.1849 (0.044–0.769) 0.020
p53 0.2891 (0.156–0.598) 0.033 0.3561 (0.278–0.681) 0.041
Grade 2.5091 (1.384–4.547) 0.002 3.4061 (1.319–8.797) 0.011
TNM stage 1.549 (0.781–3.069) 0.210 1.204 (0.479–3.025) 0.693
ER status 4.331 (1.895–9.898) <0.001 2.036 (0.5423–7.643) 0.292
AI 2.3561 (1.231–3.345) 0.841 1.8911 (1.761–2.234) 1.691
Table 3 Patient survival status in different phenotypes of p27, p53 and AI
Phenotype Alive and well (%) Relapse (%) Death (%)
p27(H) AI(H) 100 0 0
p27(L) AI(L) 52 24 24
p27(L) AI(H) 80 14 6
p27(H) AI(L) 89 11 0
p27(H) p53(L) 93 7 0
p27(L) p53(H) 45 33 22
p27(H) p53(H) 75 0 25
p27(L) p53(L) 71 24 5
H, high expression; L, low expression.
Table 4 Univariate analysis for prognostic factors for breast cancer patients
P-values
Factors analysis Relapse-free survival Overall survival
LN status 0.0032 0.0024
Tumour size 0.0011 0.0931
ER status 0.1709 0.0040
p27 0.0001 0.0012
p53 0.0252 0.0431
AI 0.0095 0.03411576 J Wu et al
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The univariate relationships between p27, p53, AI and traditional
tumour characteristics and relapse-free and overall survival are
given in Table 4. As shown in this table, p27, AI, p53 and lymph
node status were significant prognostic factors for both relapse-free
and overall survival.
Cox’s proportional hazard model was used to assess the impor-
tance of the p27, p53, AI and traditional tumour characteristics in a
multivariate analysis (Table 5). Lymph node status, p27 and p53
were significantly predictive of both relapse-free and overall
survival, while AI, ER status and age did not prove to be indepen-
dent prognostic markers. In a subsequent breakdown of this
analysis into lymph node-negative (Table 6) and lymph node-
positive (Table 7) patients, both p27 and p53 were independent
prognostic markers of both relapse-free and overall survival.
When p27 and AI status were examined separately in groups of
patients who received or did not receive chemotherapy (including
tamoxifen) and related to relapse-free and overall survival, low
p27 and low AI were predictive of maximum benefit of
chemotherapy (P < 0.05) (Figures 3 and 4).
DISCUSSION
Human breast carcinoma is biologically heterogeneous, and its
clinical course may vary from an indolent slowly progressive one
to a course associated with rapid progression and metastatic
spread. Clinical parameters such as tumour size and lymph node
status have long been used to characterize breast cancer pheno-
types in relation to prognosis (Saez et al, 1988). It is important,
however, especially in node-negative patients, to establish 
prognostic and predictive factors which will define subgroups of
patients. As the staging and therapy of breast cancer patients is
currently undergoing an evolution toward breast conservation,
more limited axillary node dissection (sentinel node sampling) 
and more frequent use of both neoadjuvant and adjuvant
chemotherapy, it is even more imperative to define better prog-
nostic and predictive markers that can be applied to the actual
primary breast cancer tissue specimen (Robertson et al, 1997). In
the present study, we investigated apoptosis, expression of p27Kip1
and p53 for their prognostic and predictive significance.
It seems logical that an analysis of cell proliferation and cell
death in human breast cancer would result in prognostic and
predictive markers. Normal mammary epithelial homeostasis is
dependent not only on the rate of cell proliferation but also on
apoptosis – a genetically programmed process of autonomous cell
death (Geske et al, 1994). Defective regulation of apoptosis and
proliferation may exert an important effect in breast cancer.
Reduced apoptosis may lead to a shift in tissue kinetics towards 
the expansion of cell numbers, and also to the preservation of
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genetically aberrant cells, favouring neoplastic development. In a
previous study, we have shown breast cancer cells exhibit reduced
apoptosis compared to normal breast epithelium (Shao et al,
1996). Investigators in another study reported reduced breast
epithelial cell apoptosis in association with fibrocystic disease and
an increased risk of carcinoma (Allan et al, 1992). Other investiga-
tors have shown that the inhibition of apoptosis is linked to tumour
promotion (Tomei et al, 1988). Higher apoptotic counts have also
been observed to be associated with a better outcome in neuroblas-
toma (Hoehner et al, 1995) and colon cancer (Langlois et al,
1997). In this study, we have demonstrated that high AI was asso-
ciated with lower tumour grade and lack of axillary lymph node
metastasis. In univariate analysis, high AI correlated with
increased relapse-free and overall survival. Although multivariate
analysis did not show AI as an independent prognostic marker, our
results suggest that AI at least partially influences clinical
outcome. Low AI was predictive of chemotherapy benefit. Our
results can be explained by the hypothesis that cells with low
apoptosis have an increased propensity for metastatic survival
(Raff et al, 1992) but greater susceptibility to the apoptosis-
inducing effects of chemotherapy.
Cell proliferation is governed by the synthesis and activation of
a number of positive and negative regulators of cell cycle progres-
sion (Hartwell et al, 1994). A number of cyclin/CDK inhibitors
have been found associated with the G1 cell cycle period (Hunt et
al, 1993; Wage et al, 1994). One of these inhibitors, p27Kip1, was
identified by a number of investigators independently and appears
to play a major role in the regulation of cyclin CDK complex
activity in this phase of the cell cycle (Polyk et al, 1994a,b;
Toyoshima et al, 1994). Overexpression of p27 in mammalian
cells induces a G1 block of the cell cycle and inhibits growth of a
number of cancer cells (Polyk et al, 1994a,b; Toyoshima et al,
1994). p27 immunoreactivity, however, has been investigated in
only a limited number of human cancers (Catzavelos et al, 1997;
Esposito et al, 1997; Loda et al, 1997; Porter et al, 1997; Tan et al,
1997). Low p27 expression in colon cancer has been related to
aggressiveness and decreased survival (Loda et al, 1997). In
human breast cancer, low p27 is associated with tumour progres-
sion (Catzavelos et al, 1997). In small invasive breast cancers, p27
expression was found to be an independent prognostic marker
(Tan et al, 1997). It has also been shown that the expression of p27
and cyclin E, alone and in combination, correlates with survival in
young breast cancer patients (Porter et al, 1997). In our present
study, we have demonstrated that low p27 strongly correlates with
lymph node metastasis while high p27 correlates with improved
patient survival. In node-negative patients where there is a great
need for prognostic markers, our study demonstrated that p27 
is an independent prognostic marker in multivariate analysis.
Furthermore, p27 was predictive of chemotherapy benefit.
As p27 belongs to the same family of cki’s as p21, and p21 is
known to be a downstream effector of p53, there could potentially
be a similar relationship between p27 and p53. In our study, we, in
fact, found evidence of this downstream relationship. We found an
inverse relationship between p27 and p53 expression in human
breast carcinomas: low p27 expression was associated with p53
overexpression, a marker of p53 mutational inactivation, while
high p27 expression was associated with normal p53 expression. It
has been shown that overexpression of p27Kip1 in cancer cells
results in G1-S arrest and induction of apoptosis (Katayose et al,
1997). In our study, we found that p27 expression strongly corre-
lated with AI (P < 0.05).
In the present study, we stratified our patients into p27/AI and
p27/p53 phenotypes (L vs H) and examined their relationship to
clinical outcome. We found that p27(L)/AI(L) and p27(L)/p53(H)
status had the worst prognosis. It is interesting that the
p27(L)/p53(L) phenotype also had a particularly high relapse
rate. As low p53 could reflect not only normal or wild-type p53
expression but absence of p53 expression (from homozygous
mutations or deletions), p53 of the latter categories could explain
this phenotype.
In conclusion, our studies show that p27 and AI are potentially
important prognostic and predictive markers of outcome in breast
cancer patients. It must be remembered, however, that these
conclusions must be tempered with the knowledge that our study
was a retrospective one. A prospective randomized study is very
much needed to examine these results more thoroughly, and
presently we are in the process of conducting such a study.
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